CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.7B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.04: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.33%Above 5Y avg (1.70%)
Annual Rate
CNY 0.15Paid annual
Payout Ratio
77.7%Moderate
Payback Period
28.8 yr
Last Ex-Dividend
Jun 24, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.45BCNY1.70B · vs all stocks (USD)
Trailing P/E
23.74xRevenue (TTM)
6.69BCNY995.48M · vs all stocks (USD)
Profit Margin
7.22%Beta
0.2050xvs all stocks
52-Week Change
-3.01%vs all stocks
Market Capitalization
11.45BCNY1.70B · vs all stocks (USD)
Enterprise Value
10.44BCNY1.55B · vs all stocks (USD)
Trailing P/E
23.74xForward P/E
14.09xPrice to Sales (TTM)
1.71xPrice to Book (MRQ)
1.58xEnterprise to Revenue
1.56xEnterprise to EBITDA
11.33xGross Margin
56.74%Profit Margin
7.22%Operating Margin
13.40%Return on Assets (TTM)
3.66%Return on Equity (TTM)
6.93%Revenue (TTM)
6.69BCNY995.48M · vs all stocks (USD)
Revenue per Share (TTM)
2.68CNYUpdated Aug 20, 2026Quarterly Revenue Growth
13.10%Gross Profit (TTM)
3.58BCNY532.40M · vs all stocks (USD)
EBITDA (TTM)
779.93MCNY115.98M · vs all stocks (USD)
Net Income (TTM)
483.42MCNY71.89M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.80%Operating Cash Flow (TTM)
1.01BCNY150.61M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
456.20MCNY67.84M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1500CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
3.33%vs all stocks
5-Year Average Dividend Yield
1.70%vs all stocks
Payout Ratio
77.72%Minority Interest (Equity)
105.11MCNYFY2025 · Dec 31, 2025Revenue
6.47BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
3.02BCNYFY2025 · Dec 31, 2025Gross Profit
3.45BCNYFY2025 · Dec 31, 2025Operating Income
624.18MCNY92.82M · vs all stocks (USD)
Pre-tax Income
645.17MCNYFY2025 · Dec 31, 2025Income Tax Expense
153.62MCNYFY2025 · Dec 31, 2025Net Income
491.55MCNYFY2025 · Dec 31, 2025EBIT
652.96MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.03BCNYFY2025 · Dec 31, 2025Research & Development
262.22MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.55BCNYFY2025 · Dec 31, 2025Other Operating Expenses
87.66MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
17.47MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
7.79MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
2.50BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.50BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
491.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-17.19MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
671.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
549.84MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.60BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
491.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.59MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
156.52MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
15.90MCNYFY2025 · Dec 31, 2025Capital Expenditures
-121.73MCNYFY2025 · Dec 31, 2025Sale of Investments
55.90MCNYFY2025 · Dec 31, 2025Other Investing Activity
1.29MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-64.54MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
282.03MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-403.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-383.64MCNYFY2025 · Dec 31, 2025Other Financing Charges
18.58MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-487.01MCNYFY2025 · Dec 31, 2025Shares Outstanding
2.54BSharesUpdated Aug 20, 2026Float Shares
1.64BSharesUpdated Aug 20, 2026% Held by Insiders
36.26%vs all stocks
% Held by Institutions
5.59%vs all stocks
Total Cash (MRQ)
856.44MCNY127.36M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3380CNYUpdated Aug 20, 2026Total Debt (MRQ)
150.41MCNY22.37M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0204xCurrent Ratio (MRQ)
1.98xBook Value per Share (MRQ)
2.86CNYUpdated Aug 20, 2026Total Assets
9.98BCNY1.48B · vs all stocks (USD)
Total Current Assets
4.56BCNYFY2025 · Dec 31, 2025Total Liabilities
2.83BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.43BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
393.78MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.44BCNYFY2025 · Dec 31, 2025Cash
1.65BCNYFY2025 · Dec 31, 2025Cash Equivalents
21.10MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.67BCNYFY2025 · Dec 31, 2025Accounts Receivable
990.92MCNYFY2025 · Dec 31, 2025Inventory
1.23BCNYFY2025 · Dec 31, 2025Accounts Payable
955.57MCNYFY2025 · Dec 31, 2025Short-term Debt
262.72MCNYFY2025 · Dec 31, 2025Other Current Liabilities
4.10MCNYFY2025 · Dec 31, 2025Long-term Debt
40.99MCNYFY2025 · Dec 31, 2025Common Stock (Book)
2.53BCNYFY2025 · Dec 31, 2025Retained Earnings
3.53BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.15BCNY1.06B · vs all stocks (USD)
52-Week Low
3.77CNYUpdated Aug 20, 202652-Week High
5.17CNYUpdated Aug 20, 202652-Week Change
-3.01%vs all stocks
Beta
0.2050xvs all stocks
50-Day MA
4.25CNYUpdated Aug 20, 2026200-Day MA
4.42CNYUpdated Aug 20, 2026Avg 10-Day Volume
148.95MSharesUpdated Aug 20, 2026Avg 30-Day Volume
87.40MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.1900CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: 0.07
Financial Health
Altman Z-Score 4.04: safe zoneNotable
Altman Z-Score: 4.04
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.7B, above the global median of $1.15BNotable
Market cap (USD): 1,702,547,993.348Global Median: 1,146,734,693.424
Revenue is $995.48M, above the global median of $520.53MNotable
Revenue (USD): 995,483,793.915Global Median: 520,528,949.311
Levered free cash flow is $67.84M, above the global median of $16.24MNotable
Levered free cash flow (USD): 67,841,825.593Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cofoe Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alembic Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hubei Jumpcan Pharmaceutical Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
CIE Automotive India Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Manhattan Associates Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities